5-methyl-4-nitro-1(2)H-pyrazole-3-carboxylic acid methylamide | 68375-43-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-methyl-4-nitro-1(2)H-pyrazole-3-carboxylic acid methylamide
• 英文别名: N,5-dimethyl-4-nitro-1H-pyrazole-3-carboxamide
• CAS: 68375-43-9
• 化学式: C₆H₈N₄O₃
• 分子量: 184.155
• InChiKey: VPVQEBWABVWGIJ-UHFFFAOYSA-N

物化性质

• 沸点：
  408.5±45.0 °C(Predicted)
• 密度：
  1.422±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-methyl-4-nitro-1(2)H-pyrazole-3-carboxylic acid methylamide 在 palladium on activated charcoal sodium tetrahydroborate 作用下， 生成 4-氨基-N,5-二甲基-1H-吡唑-3-甲酰胺
  参考文献：
  名称：

  吡唑相关的核苷。某些取代的吡唑和吡唑并[4,3-d] -1,2,3-三嗪-4-酮核苷的合成及抗病毒/抗肿瘤活性。

  摘要：

  制备了几种吡唑和吡唑并[4,3-d] -1,2,3-三嗪-4-一核糖核苷，并测试了其抗病毒/抗肿瘤活性。通过标准方法制备适当的杂环碱。吡唑6a-e，g，i和吡唑并[4,3-d] -1,2,3-三嗪-4-酮12f-1的糖基化反应，是通过六甲基二硅氮烷与1-β-O-乙酰基-甲硅烷基化作用介导的2,3,5-三-O-苯甲酰基-D-呋喃呋喃糖的相应糖苷7a-e，g，8g，i，13f，h，k和14f的收率很高，但不能应用于化合物12g ，i，j，l。为了克服这种情况，需要一种不同的策略，涉及适当的吡唑糖苷9和10的制备，重氮化和原位环化。此外，具有通式5的衍生物不仅被认为是3的合成中的合成中间体，而且还被认为是利巴韦林4的碳生物等排体。在体外对所有化合物进行了细胞抑制和抗病毒活性的评价。所产生的吡唑并[4，3-d] -1,2,3-三嗪-4-酮核苷基本上没有任何活性。仅15h，k显示出对T细胞的中等细胞

  DOI：

  10.1021/jm00083a017
• 作为产物：
  描述：

  3-甲基-4-硝基-1H-吡唑-5-羧酸 在 氯化亚砜 作用下， 以 乙醚 、 水 为溶剂， 反应 12.0h， 生成 5-methyl-4-nitro-1(2)H-pyrazole-3-carboxylic acid methylamide
  参考文献：
  名称：

  Synthesis and anti-TMV activity of novel N-(3-alkyl-1H-pyrazol-4-yl)-3-alkyl-4-substituted-1H-pyrazole-5-carboxamides

  摘要：

  In order to investigate the biological activity of novel bis-pyrazole compounds, a series of N-(3-alkyl-5-(N-methylcarbamyl)-1 H-pyrazol-4-yl)-3-alkyl-4-substituted-1H-pyrazole-5-carboxamides were designed and synthesized with ethyl 3-alkyl-1H-pyrazole-5-carboxylate 1 as starting materials. N-Methyl-3-alkyl-4-amino-1H-pyrazole-5-carboxamides 6 were obtained from 1 via 5 steps. 3-Alkyl-4-substitued-1H-pyrazole-5-carboxyl chlorides 4a, 4b, 11a, 11b, 11c or 12 were also obtained from 1 via several steps. Target compounds 7a-7g were obtained after the reaction of 6 with the above 1H-pyrazole-5-carboxyl chlorides. Preliminary bioassay showed some compounds possessing good inactivation effect against TMV (tobacco mosaic virus). Compound 7a showed higher activity superior to ningnanmycin at a concentration of 5.0 x 10(-4) g/mL and equal activity it 1.0 x 10(-4) g/mL; 7b and 7c showed equal activity to virazole both at concentrations of 5.0 x 10(-4) g/mL and 1.0 x 10(-4) g/ML. (C) 2012 De Kai Yuan. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  DOI：

  10.1016/j.cclet.2012.04.010

文献信息

• [EN] GLUCOSE TRANSPORT INHIBITORS<br/>[FR] INHIBITEURS DE TRANSPORT DU GLUCOSE
  申请人：BAYER PHARMA AG

  公开号：WO2016202898A1

  公开（公告）日：2016-12-22

  The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及选择性抑制葡萄糖转运蛋白1（GLUT1）的化合物，涉及制备该类化合物的方法，涉及包含该类化合物的药物组合物和药物组合物，涉及利用该类化合物制造用于治疗或预防疾病的药物组合物，以及用于制备该类化合物的中间化合物。
• Pyrazole-related nucleosides. Synthesis and antiviral/antitumor activity of some substituted pyrazole and pyrazolo[4,3-d]-1,2,3-triazin-4-one nucleosides
  作者：Stefano Manfredini、Rita Bazzanini、Pier Giovanni Baraldi、Mario Guarneri、Daniele Simoni、Maria E. Marongiu、Alessandra Pani、Paolo La Colla、Enzo Tramontano

  DOI：10.1021/jm00083a017

  日期：1992.3

  preparation, diazotization, and in situ cyclization of opportune pyrazole glycosides 9 and 10 was required. Moreover derivatives having the general formula 5 were considered not only as synthetic intermediates in the synthesis of 3 but also as carbon bioisosteres of ribavirin 4. All compounds were evaluated in vitro for cytostatic and antiviral activity. The pyrazolo[4,3-d]-1,2,3-triazin-4-one nucleosides that

  制备了几种吡唑和吡唑并[4,3-d] -1,2,3-三嗪-4-一核糖核苷，并测试了其抗病毒/抗肿瘤活性。通过标准方法制备适当的杂环碱。吡唑6a-e，g，i和吡唑并[4,3-d] -1,2,3-三嗪-4-酮12f-1的糖基化反应，是通过六甲基二硅氮烷与1-β-O-乙酰基-甲硅烷基化作用介导的2,3,5-三-O-苯甲酰基-D-呋喃呋喃糖的相应糖苷7a-e，g，8g，i，13f，h，k和14f的收率很高，但不能应用于化合物12g ，i，j，l。为了克服这种情况，需要一种不同的策略，涉及适当的吡唑糖苷9和10的制备，重氮化和原位环化。此外，具有通式5的衍生物不仅被认为是3的合成中的合成中间体，而且还被认为是利巴韦林4的碳生物等排体。在体外对所有化合物进行了细胞抑制和抗病毒活性的评价。所产生的吡唑并[4，3-d] -1,2,3-三嗪-4-酮核苷基本上没有任何活性。仅15h，k显示出对T细胞的中等细胞
• GLUCOSE TRANSPORT INHIBITORS
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20170037028A1

  公开（公告）日：2017-02-09

  The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
• Synthesis and anti-TMV activity of novel N-(3-alkyl-1H-pyrazol-4-yl)-3-alkyl-4-substituted-1H-pyrazole-5-carboxamides
  作者：Da Qiang Zhang、Gao Fei Xu、Zhi Jin Fan、Dao Quan Wang、Xin Ling Yang、De Kai Yuan

  DOI：10.1016/j.cclet.2012.04.010

  日期：2012.6

  In order to investigate the biological activity of novel bis-pyrazole compounds, a series of N-(3-alkyl-5-(N-methylcarbamyl)-1 H-pyrazol-4-yl)-3-alkyl-4-substituted-1H-pyrazole-5-carboxamides were designed and synthesized with ethyl 3-alkyl-1H-pyrazole-5-carboxylate 1 as starting materials. N-Methyl-3-alkyl-4-amino-1H-pyrazole-5-carboxamides 6 were obtained from 1 via 5 steps. 3-Alkyl-4-substitued-1H-pyrazole-5-carboxyl chlorides 4a, 4b, 11a, 11b, 11c or 12 were also obtained from 1 via several steps. Target compounds 7a-7g were obtained after the reaction of 6 with the above 1H-pyrazole-5-carboxyl chlorides. Preliminary bioassay showed some compounds possessing good inactivation effect against TMV (tobacco mosaic virus). Compound 7a showed higher activity superior to ningnanmycin at a concentration of 5.0 x 10(-4) g/mL and equal activity it 1.0 x 10(-4) g/mL; 7b and 7c showed equal activity to virazole both at concentrations of 5.0 x 10(-4) g/mL and 1.0 x 10(-4) g/ML. (C) 2012 De Kai Yuan. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.